Idelalisib
Sign in to save this workspacePrimary targets: PI3K · FDA status: FDA Approved
Selectivity scorecard
KISS
100.00
Gini
0.701
CATDS
0.031
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Idelalisib. Strongest target: PKG2_PRKG2 at 27.4% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | PKG2_PRKG2 | 27.4% | 72.6% |
| 2 | PKN3_PRK3 | 18.6% | 81.4% |
| 3 | DRAK1_STK17A | 16.6% | 83.4% |
| 4 | BMPR2 | 15.6% | 84.4% |
| 5 | ERK2_MAPK1 | 15.4% | 84.6% |
| 6 | CAMK1B | 15.0% | 85.0% |
| 7 | RIPK4 | 12.1% | 87.9% |
| 8 | MLK3_MAP3K11 | 11.0% | 89.0% |
| 9 | MYO3A | 10.8% | 89.2% |
| 10 | OSR1_OXSR1 | 10.6% | 89.4% |
| 11 | FAK_PTK2 | 10.6% | 89.4% |
| 12 | PDGFRB | 10.6% | 89.4% |
| 13 | EPHB1 | 10.0% | 90.0% |
| 14 | PDK2_PDHK2 | 10.0% | 90.0% |
| 15 | MLK2_MAP3K10 | 10.0% | 90.0% |
| 16 | DAPK2 | 9.9% | 90.1% |
| 17 | BRK | 9.9% | 90.1% |
| 18 | STK25_YSK1 | 9.9% | 90.1% |
| 19 | DNA_PK | 9.5% | 90.5% |
| 20 | RIPK2 | 9.0% | 91.0% |
Selectivity landscape
Where Idelalisib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Idelalisib.
Annotations
Sign in to read and post annotations.
Loading…